Selective Inhibition of Matrix Metalloproteinase-9 Attenuates Secondary Damage Resulting from Severe Traumatic Brain Injury

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Hadass, Orr ^a,b   Tomlinson, Brittany N ^a,b   Gooyit, Major ^c   Chen, Shanyan ^a,b   Purdy, Justin J ^a   Walker, Jennifer M ^b   Zhang, Chunyang ^a   Giritharan, Andrew B ^a   Purnell, Whitley ^a   Robinson II, Christopher R ^a   Shin, Dmitriy ^a   Schroeder, Valerie A ^c   Suckow, Mark A ^c   Simonyi, Agnes ^a   Sun, Grace Y ^a   Mobashery, Shahriar ^c   Cui, Jiankun ^a   Chang, Mayland ^c   Gu, Zezong ^a  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[(4 PHENOXYPHENYL)SULFONYL]METHYL]THIIRANE; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; SB 3CT COMPOUND; SINGLE HETEROCYCLIC RINGS; SULFONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN DAMAGE; CELL LOSS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; ENZYME INHIBITION; INJURY SEVERITY; MALE; MICROGLIA; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SPATIAL LEARNING; SPATIAL MEMORY; TRAUMATIC BRAIN INJURY; ANALYSIS OF VARIANCE; ANIMAL; BLOOD BRAIN BARRIER; BRAIN; BRAIN INJURY; DRUG EFFECTS; ENZYME ACTIVATION; FLUORESCENCE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MAZE TEST; METABOLISM; PATHOLOGY;

ANALYSIS OF VARIANCE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN INJURIES; ENZYME ACTIVATION; FLUORESCENCE; HETEROCYCLIC COMPOUNDS, 1-RING; HISTOLOGICAL TECHNIQUES; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MAZE LEARNING; MICE; SULFONES;

EID: 84886057065     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076904     Document Type: Article

References (48)

1. Summers CR, Ivins B, Schwab KA, (2009) Traumatic brain injury in the United States: an epidemiologic overview. Mt Sinai J Med 76(2): 105-110.
2. Loane DJ, Faden AI, (2010) Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol Sci 31(12): 596-604.
3. Zhang H, Adwanikar H, Werb Z, Noble-Haeusslein LJ, (2010) Matrix metalloproteinases and neurotrauma: evolving roles in injury and reparative processes. Neuroscientist 16(2): 156-170.
4. Yong VW, (2005) Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 6(12): 931-944.
5. Kessenbrock K, Plaks V, Werb Z, (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141(1): 52-67.
6. Mott JD, Werb Z, (2004) Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16(5): 558-564.
7. Chen ZL, Strickland S, (1997) Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 91(7): 917-925.
8. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, et al. (2002) S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297(5584): 1186-1190.
9. Yu F, Kamada H, Niizuma K, Endo H, Chan PH, (2008) Induction of mmp-9 expression and endothelial injury by oxidative stress after spinal cord injury. J Neurotrauma 25(3): 184-195.
10. Noble LJ, Donovan F, Igarashi T, Goussev S, Werb Z, (2002) Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J Neurosci 22(17): 7526-7535.
11. Kim GW, Gasche Y, Grzeschik S, Copin JC, Maier CM, et al. (2003) Neurodegeneration in striatum induced by the mitochondrial toxin 3-nitropropionic acid: role of matrix metalloproteinase-9 in early blood-brain barrier disruption? J Neurosci 23(25): 8733-8742.
12. Grossetete M, Phelps J, Arko L, Yonas H, Rosenberg GA, (2009) Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury. Neurosurgery 65(4): 702-708.
13. Pardridge WM, (2007) Blood-brain barrier delivery. Drug Discov Today 12(1-2): 54-61.
14. Brown S, Bernardo MM, Li ZH, Kotra LP, Tanaka Y, et al. (2000) Potent and selective mechanism-based inhibition of gelatinases. J Am Chem Soc 122: 6799-6800.
15. Gu Z, Cui J, Brown S, Fridman R, Mobashery S, et al. (2005) A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 25(27): 6401-6408.
16. Cui J, Chen S, Zhang C, Meng F, Wu W, et al. (2012) Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia. Mol Neurodegener 7(1): 21.
17. Gooyit M, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, et al. (2012) Selective gelatinase inhibitor neuroprotective agents cross the blood-brain barrier. ACS Chem Neurosci 3(10): 730-736.
18. Lee M, Villegas-Estrada A, Celenza G, Boggess B, Toth M, et al. (2007) Metabolism of a highly selective gelatinase inhibitor generates active metabolite. Chem Biol Drug Des 70(5): 371-382.
19. Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, et al. (2010) Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 68(3): 409-427.
20. Lam CK, Yoo T, Hiner B, Liu Z, Grutzendler J, (2010) Embolus extravasation is an alternative mechanism for cerebral microvascular recanalization. Nature 465(7297): 478-482.
21. Brody DL, MacDonald C, Kessens CC, Yuede C, Parsadanian M, et al. (2007) Electromagnetic controlled cortical impact device for precise, graded experimental traumatic brain injury. J Neurotrauma 24(4): 657-673.
22. Wang X, Jung J, Asahi M, Chwang W, Russo L, et al. (2000) Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J Neurosci 20(18): 7037-7042.
23. Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S, (2003) Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 34(9): 2165-2170.
24. Montaner J, Alvarez-Sabin J, Molina CA, Angles A, Abilleira S, et al. (2001) Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32(12): 2762-2767.
25. Switzer JA, Hess DC, Ergul A, Waller JL, Machado LS, et al. (2011) Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. Stroke 42(9): 2633-2635.
26. Toth M, Bernardo MM, Gervasi DC, Soloway PD, Wang Z, et al. (2000) Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (membrane type 1)-MMP-dependent activation of pro-MMP-2. J Biol Chem 275(52): 41415-41423.
27. Zhang QG, Laird MD, Han D, Nguyen K, Scott E, et al. (2012) Critical role of NADPH oxidase in neuronal oxidative damage and microglia activation following traumatic brain injury. PLoS One 7(4): e34504.
28. Dohi K, Ohtaki H, Nakamachi T, Yofu S, Satoh K, et al. (2010) Gp91phox (NOX2) in classically activated microglia exacerbates traumatic brain injury. J Neuroinflamm 7: 41.
29. Sheng W, Zong Y, Mohammad A, Ajit D, Cui J, et al. (2011) Pro-inflammatory cytokines and lipopolysaccharide induce changes in cell morphology, and upregulation of ERK1/2, iNOS and sPLA(2)-IIA expression in astrocytes and microglia. J Neuroinflamm 8: 121.
30. Liu H, Shubayev V, (2011) Matrix metalloproteinase-9 controls proliferation of NG2+ progenitor cells immediately after spinal cord injury. Exp Neurol 231(2): 236-246.
31. Kettenmann H, (2007) Neuroscience: the brain's garbage men. Nature 446(7139): 987-989.
32. Block ML, Hong JS, (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76(2): 77-98.
33. Qiu LB, Zhou Y, Wang Q, Yang LL, Liu HQ, et al. (2011) Synthetic gelatinases inhibitor attenuates electromagnetic pulse-induced blood-brain barrier disruption by inhibiting gelatinases-mediated ZO-1 degradation in rats. Toxicology 285(1-2): 31-38.
34. del Zoppo GJ, Milner R, Mabuchi T, Hung S, Wang X, et al. (2007) Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke 38(2 Suppl): 646-651.
35. Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, et al. (2006) Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 12(4): 441-445.
36. Rosenberg GA, (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 8(2): 205-216.
37. Buss A, Pech K, Kakulas BA, Martin D, Schoenen J, et al. (2007) Matrix metalloproteinases and their inhibitors in human traumatic spinal cord injury. BMC Neurol 7: 17.
38. Forbes C, Shi Q, Fisher JF, Lee M, Hesek D, et al. (2009) Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases. Chem Biol Drug Des 74(6): 527-534.
39. Guo Z, Sun X, He Z, Jiang Y, Zhang X, et al. (2009) Matrix metalloproteinase-9 potentiates early brain injury after subarachnoid hemorrhage. Neurol Res 32(7): 715-720.
40. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, et al. (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 485(7399): 512-516.
41. Liu J, Jin X, Liu KJ, Liu W, (2012) Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage. J Neurosci 32(9): 3044-3057.
42. Pardridge WM, (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2(1): 3-14.
43. Lee M, Celenza G, Boggess B, Blase J, Shi Q, et al. (2009) A potent gelatinase inhibitor with anit-tumor invasive activity and its metabolic disposition. Chem Biol Drug Des 73: 189-202.
44. Garden GA, Budd SL, Tsai E, Hanson L, Kaul M, et al. (2002) Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci 22(10): 4015-4024.
45. Helton R, Cui J, Scheel JR, Ellison JA, Ames C, et al. (2005) Brain-specific knock-out of hypoxia-inducible factor-1alpha reduces rather than increases hypoxic-ischemic damage. J Neurosci 25(16): 4099-4107.
46. Yagi Y, Gilbertson JR (2008) A relationship between slide quality and image quality in whole slide imaging (WSI). Diagn Pathol (Suppl 1): S12.
47. Fox GB, Fan L, Levasseur RA, Faden AI, (1998) Sustained sensory/motor and cognitive deficits with neuronal apoptosis following controlled cortical impact brain injury in the mouse. J Neurotrauma 15(8): 599-614.
48. Walker JM, Fowler SW, Miller DK, Sun AY, Weisman GA, et al. (2011) Spatial learning and memory impairment and increased locomotion in a transgenic amyloid precursor protein mouse model of Alzheimer's disease. Behav Brain Res 222(1): 169-175.